Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy

Johanna K. Björk, Ilmari Ahonen, Tuomas Mirtti, Andrew Erickson, Antti Rannikko, Anna Butzow, Stig Nordling, Johan Lundin, Mikael Lundin, Lea Sistonen, Matthias Nees, Malin Akerfelt

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

Prostate cancer is a highly heterogeneous disease and the clinical outcome is varying. While current prognostic tools are regarded insufficient, there is a critical need for markers that would aid prognostication and patient risk-stratification. Heat shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression datasets on prostate cancer. Clinical validation was performed on tissue microarrays from independent cohorts: one constructed from radical prostatectomies from 478 patients with long term follow-up, and another comprising of regionally advanced to distant metastatic samples. Associations with clinical variables and disease outcomes were investigated. Increased nuclear HSF1 expression correlated with disease advancement and aggressiveness and was, independently from established clinicopathological variables, predictive of both early initiation of secondary therapy and poor disease-specific survival. In a joint model with the clinical Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained a predictive factor of shortened disease-specific survival. The results suggest that nuclear HSF1 expression could serve as a novel prognostic marker for patient risk-stratification on disease progression and survival after radical prostatectomy.
Alkuperäiskielienglanti
LehtiOncotarget
Vuosikerta9
Numero58
Sivut31200-31213
Sivumäärä14
ISSN1949-2553
DOI - pysyväislinkit
TilaJulkaistu - 2018
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Lisätietoja

Bjork, Johanna K Ahonen, Ilmari Mirtti, Tuomas Erickson, Andrew Rannikko, Antti Butzow, Anna Nordling, Stig Lundin, Johan Lundin, Mikael Sistonen, Lea Nees, Matthias Akerfelt, Malin eng Oncotarget. 2018 Jul 27;9(58):31200-31213. doi: 10.18632/oncotarget.25756. eCollection 2018 Jul 27.

Tieteenalat

  • 3122 Syöpätaudit

Lainaa tätä

Björk, Johanna K. ; Ahonen, Ilmari ; Mirtti, Tuomas ; Erickson, Andrew ; Rannikko, Antti ; Butzow, Anna ; Nordling, Stig ; Lundin, Johan ; Lundin, Mikael ; Sistonen, Lea ; Nees, Matthias ; Akerfelt, Malin. / Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. Julkaisussa: Oncotarget. 2018 ; Vuosikerta 9, Nro 58. Sivut 31200-31213.
@article{8d09de6b332746bcb97a1d5429ea79e3,
title = "Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy",
abstract = "Prostate cancer is a highly heterogeneous disease and the clinical outcome is varying. While current prognostic tools are regarded insufficient, there is a critical need for markers that would aid prognostication and patient risk-stratification. Heat shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression datasets on prostate cancer. Clinical validation was performed on tissue microarrays from independent cohorts: one constructed from radical prostatectomies from 478 patients with long term follow-up, and another comprising of regionally advanced to distant metastatic samples. Associations with clinical variables and disease outcomes were investigated. Increased nuclear HSF1 expression correlated with disease advancement and aggressiveness and was, independently from established clinicopathological variables, predictive of both early initiation of secondary therapy and poor disease-specific survival. In a joint model with the clinical Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained a predictive factor of shortened disease-specific survival. The results suggest that nuclear HSF1 expression could serve as a novel prognostic marker for patient risk-stratification on disease progression and survival after radical prostatectomy.",
keywords = "biomarker heat shock factor predictive marker prostate cancer tissue microarray (TMA) interest., 3122 Cancers",
author = "Bj{\"o}rk, {Johanna K.} and Ilmari Ahonen and Tuomas Mirtti and Andrew Erickson and Antti Rannikko and Anna Butzow and Stig Nordling and Johan Lundin and Mikael Lundin and Lea Sistonen and Matthias Nees and Malin Akerfelt",
note = "Bjork, Johanna K Ahonen, Ilmari Mirtti, Tuomas Erickson, Andrew Rannikko, Antti Butzow, Anna Nordling, Stig Lundin, Johan Lundin, Mikael Sistonen, Lea Nees, Matthias Akerfelt, Malin eng Oncotarget. 2018 Jul 27;9(58):31200-31213. doi: 10.18632/oncotarget.25756. eCollection 2018 Jul 27.",
year = "2018",
doi = "10.18632/oncotarget.25756",
language = "English",
volume = "9",
pages = "31200--31213",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "58",

}

Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. / Björk, Johanna K.; Ahonen, Ilmari; Mirtti, Tuomas; Erickson, Andrew; Rannikko, Antti; Butzow, Anna; Nordling, Stig; Lundin, Johan; Lundin, Mikael; Sistonen, Lea; Nees, Matthias; Akerfelt, Malin.

julkaisussa: Oncotarget, Vuosikerta 9, Nro 58, 2018, s. 31200-31213.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy

AU - Björk, Johanna K.

AU - Ahonen, Ilmari

AU - Mirtti, Tuomas

AU - Erickson, Andrew

AU - Rannikko, Antti

AU - Butzow, Anna

AU - Nordling, Stig

AU - Lundin, Johan

AU - Lundin, Mikael

AU - Sistonen, Lea

AU - Nees, Matthias

AU - Akerfelt, Malin

N1 - Bjork, Johanna K Ahonen, Ilmari Mirtti, Tuomas Erickson, Andrew Rannikko, Antti Butzow, Anna Nordling, Stig Lundin, Johan Lundin, Mikael Sistonen, Lea Nees, Matthias Akerfelt, Malin eng Oncotarget. 2018 Jul 27;9(58):31200-31213. doi: 10.18632/oncotarget.25756. eCollection 2018 Jul 27.

PY - 2018

Y1 - 2018

N2 - Prostate cancer is a highly heterogeneous disease and the clinical outcome is varying. While current prognostic tools are regarded insufficient, there is a critical need for markers that would aid prognostication and patient risk-stratification. Heat shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression datasets on prostate cancer. Clinical validation was performed on tissue microarrays from independent cohorts: one constructed from radical prostatectomies from 478 patients with long term follow-up, and another comprising of regionally advanced to distant metastatic samples. Associations with clinical variables and disease outcomes were investigated. Increased nuclear HSF1 expression correlated with disease advancement and aggressiveness and was, independently from established clinicopathological variables, predictive of both early initiation of secondary therapy and poor disease-specific survival. In a joint model with the clinical Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained a predictive factor of shortened disease-specific survival. The results suggest that nuclear HSF1 expression could serve as a novel prognostic marker for patient risk-stratification on disease progression and survival after radical prostatectomy.

AB - Prostate cancer is a highly heterogeneous disease and the clinical outcome is varying. While current prognostic tools are regarded insufficient, there is a critical need for markers that would aid prognostication and patient risk-stratification. Heat shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression datasets on prostate cancer. Clinical validation was performed on tissue microarrays from independent cohorts: one constructed from radical prostatectomies from 478 patients with long term follow-up, and another comprising of regionally advanced to distant metastatic samples. Associations with clinical variables and disease outcomes were investigated. Increased nuclear HSF1 expression correlated with disease advancement and aggressiveness and was, independently from established clinicopathological variables, predictive of both early initiation of secondary therapy and poor disease-specific survival. In a joint model with the clinical Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained a predictive factor of shortened disease-specific survival. The results suggest that nuclear HSF1 expression could serve as a novel prognostic marker for patient risk-stratification on disease progression and survival after radical prostatectomy.

KW - biomarker heat shock factor predictive marker prostate cancer tissue microarray (TMA) interest.

KW - 3122 Cancers

U2 - 10.18632/oncotarget.25756

DO - 10.18632/oncotarget.25756

M3 - Article

VL - 9

SP - 31200

EP - 31213

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 58

ER -